Global VC OrbiMed Leads Series A Financing In Its Second China Start-up Investment
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Life sciences and health investment firm OrbiMed announced March 8 that it has led $6.6 million series A financing for Chinese dental company EA Inc., which is focusing on providing invisible orthodontic braces to China's rising middle class
You may also be interested in...
OrbiMed Invests $8 Million In Response Biomedical To Reap Rewards Of China's Rapid Growth POCT Market
SHANGHAI - Life sciences and health investment firm OrbiMed recently injected $8 million in Response Biomedical, a Vancouver-based company providing rapid test products based on its RAMP platform and targeting the rapid growth of China's point-of-care testing market
OrbiMed Invests $8 Million In Response Biomedical To Reap Rewards Of China's Rapid Growth POCT Market
SHANGHAI - Life sciences and health investment firm OrbiMed recently injected $8 million in Response Biomedical, a Vancouver-based company providing rapid test products based on its RAMP platform and targeting the rapid growth of China's point-of-care testing market
With Investment In Bharat Serum, OrbiMed Speeds Up Its Second Deal In India In Four Months
MUMBAI - The world's largest healthcare fund OrbiMed seems to be in a hurry to invest in emerging Indian companies. Less than four months after the nearly $5 billion fund made its debut with investments in the Southern Indian clinical research outfit Ecron Acunova, it has now struck its second deal with Bharat Serums and Vaccines - a mid-sized biopharmaceutical unit that mainly manufactures niche life-saving injectable drugs